Breaking News, Collaborations & Alliances

PharmAbcine Signs CMO Contract with Binex

CDMO Binex to produce olinvacimab at its new 5,000L production line.

By: Contract Pharma

Contract Pharma Staff

PharmAbcine, a biotech company focusing on the development of antibody therapeutics, has signed a contract manufacturing organization(CMO) agreement with Binex, a biologics contract development and manufacturing organization (CDMO) company in Korea.   With the new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine’s leading antibody therapeutics pipeline in oncology, using the new 5,000L production line while it was previously produced in the 1,000L production line. This con...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters